Drug Trial Radar · NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
960
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
Jul 23, 2032
Study completion Jul 23, 2035
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Conditions
- Follicular Lymphoma
Interventions
MK-1045Biological
Intravenous (IV) infusion
RituximabBiological
IV infusion
Rituximab biosimilarBiological
IV infusion
BendamustineDrug
IV infusion
CyclophosphamideDrug
IV infusion
VincristineDrug
IV infusion
PrednisoneDrug
Per approved product label
PrednisoloneDrug
Per approved product label
Doxorubicin HydrochlorideDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 15 months
- Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 12 months
- Part 1: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 36 days
- Part 1: Complete Response (CR) RateTime frame: Up to approximately 60 months
- Part 2: Progression-Free Survival (PFS)Time frame: Up to approximately 63 months
Locations
40 sites in 14 countries. Site status is shown where the registry gives one.
City of Hope - Duarte Cancer Center ( Site 1301)
Duarte, California · Recruiting
University of Kentucky ( Site 1303)
Lexington, Kentucky · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1311)
Hackensack, New Jersey · Recruiting
Icahn School of Medicine at Mount Sinai ( Site 1325)
New York, New York · Recruiting
Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
Durham, North Carolina · Recruiting
University Hospitals of Cleveland ( Site 1321)
Cleveland, Ohio · Recruiting
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee · Recruiting
University of Texas-MD Anderson Cancer Center ( Site 1323)
Houston, Texas · Recruiting
Hospital Privado Universitario de Córdoba ( Site 0102)
Córdoba, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0105)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Aleman ( Site 0101)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Sanatorio Nuestra Senora del Rosario ( Site 0104)
Rosario, Santa Fe Province, Argentina · Recruiting
Concord Repatriation General Hospital ( Site 0202)
Concord, New South Wales, Australia · Recruiting
Box Hill Hospital ( Site 0201)
Box Hill, Victoria, Australia · Recruiting
Biocenter ( Site 0402)
Concepción, Biobio, Chile · Recruiting
Fundacion Arturo Lopez Perez FALP ( Site 0404)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 0407)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer hospital ( Site 0501)
Beijing, Beijing Municipality, China · Recruiting
Fudan University Shanghai Cancer Center ( Site 0504)
Shanghai, Shanghai Municipality, China · Recruiting
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau ( Site 0604)
Tours, Indre-et-Loire, France · Recruiting
Evangelismos General Hospital of Athens ( Site 1501)
Athens, Attica, Greece · Recruiting
General Hospital of Athens "Laiko" ( Site 1502)
Athens, Attica, Greece · Recruiting
Hadassah Medical Center ( Site 0701)
Jerusalem, Israel · Recruiting
Sheba Medical Center ( Site 0702)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center ( Site 0704)
Tel Aviv, Israel · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1601)
Rome, Lazio, Italy · Recruiting
INOC - Istituto Nazionale Oncologico Candiolo ( Site 1602)
Candiolo, Torino, Italy · Recruiting
Pratia MCM Krakow ( Site 1702)
Krakow, Lesser Poland Voivodeship, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1701)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Samsung Medical Center ( Site 0801)
Seoul, South Korea · Recruiting
Hospital Universitari Vall de Hebron ( Site 0903)
Barcelona, Spain · Recruiting
Hospital Universitario Gregorio Maranon ( Site 0902)
Madrid, Spain · Recruiting
Hospital Universitario de Salamanca ( Site 0906)
Salamanca, Spain · Recruiting
Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)
Badalona, Barcelona, Spain · Recruiting
Hospital Virgen de la Victoria ( Site 0905)
Málaga, Malaga, Spain · Recruiting
National Taiwan University Hospital ( Site 1001)
Taipei, Taiwan · Recruiting
Chang Gung Medical Foundation-Linkou Branch ( Site 1002)
Taoyuan, Taiwan · Recruiting
Hacettepe Universite Hastaneleri ( Site 1110)
Ankara, Turkey (Türkiye) · Recruiting
Sisli Florence Nightingale Hastanesi ( Site 1112)
Istanbul, Turkey (Türkiye) · Recruiting
Ondokuz Mayıs Universitesi ( Site 1113)
Samsun, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.